Skip to main content
Premium Trial:

Request an Annual Quote

New York Approves Prometheus Test for Crohn's Disease

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories today announced the New York State Department of Health has approved its proprietary Prometheus Crohn's Prognostic test for sale.

The test, which is performed in Prometheus' CLIA lab, combines six serologic markers and three genetic mutation markers and provides doctors with a personalized serologic profile for patients, the San Diego-based specialty pharmaceutical and diagnostics firm said. As a result, doctors can quantify patient risk for developing complications over time and determine appropriate treatments for patients.

In North America, between 400,000 and 600,000 people are affected by Crohn's disease, Prometheus said.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.